Prelude Corp is a leading biotech company based in Laguna Hills, CA, specializing in personalized cancer treatment solutions. They offer the innovative DCISionRT test, which accurately predicts the benefit of radiation therapy for patients with ductal carcinoma in situ (DCIS), a non-invasive form of breast cancer. Validated across multiple cohorts, DCISionRT identifies low-risk patients who can safely omit radiation therapy, while providing targeted benefits for elevated-risk patients. With a mission to improve the lives of cancer patients, Prelude Corp is at the forefront of precision medicine in the field of oncology.
Driven by a team of highly qualified professionals, Prelude Corp is dedicated to advancing the science of cancer treatment through their cutting-edge research and development. Their DCISionRT test has been validated in clinical trials and has garnered recognition from physicians for its ability to identify distinct risk profiles and guide personalized treatment decisions. With a focus on precision and innovation, Prelude Corp is revolutionizing the approach to DCIS treatment, offering patients and physicians valuable insights to optimize outcomes and improve patient care.
Generated from the website